The proprietary Arestat™ technology platform is based on a number of fundamentally novel insights into interactions between formulation excipients and proteins, allowing control of protein behaviour under various stress conditions, both in vitro and in vivo.

The application of the technology results in superior product stability in aqueous solutions, low viscosity and desirable PK/PD profiles. The technology is protected by more than 30 patent families and 28 patents granted globally and a number of additional patent applications.

  • Differentiated biosimilars with IP Protection

  • Intravenous to subcutaneous switch

  • Lyophilised powder to liquid switch

  • High concentration antibodies

  • Superior peptides

  • Thermostable vaccines and therapeutics